Why XACDURO
Fight back against Acinetobacter
Rates of Acinetobacter incidence are on the rise1
Globally, Acinetobacter baumannii is one of the six leading bacterial pathogens responsible for deaths attributable to antibiotic resistance2
Can be deadly, with an estimated 26.0% to 55.7% mortality rate3
Poses a critical threat to patients in nursing homes and hospitals, and to those who require ventilators and blood catheters4
Acinetobacter has become resistant to most antibiotics used to treat HABP/VABP, including carbapenems and third-generation cephalosporins4
The CDC classifies CRAB as an urgent public health threat.5
As of 2024, the CDC reported a significant increase in hospital‑onset carbapenem‑resistant Acinetobacter infections in 2022 compared to 2019.1
Outcomes are worse in patients with CRAB infections:*
- 2x higher odds of mortality in adult hospital patients6
- 2 days longer hospital stay on average7
In comparison to patients with carbapenem‑susceptible Acinetobacter baumannii.
Attack & restore: The dual action antibiotic treatment
XACDURO is the only treatment with durlobactam and developed for classes A, C, and D β‑lactamase inhibition to target Acinetobacter8,9
Sulbactam attacks Acinetobacter8
- Sulbactam: Bactericidal activity against Acinetobacter
- β‑lactam penicillin derivative8,10
- Mechanism of action: Inhibits penicillin‑binding proteins 1 and 3 → inhibits bacterial cell wall synthesis8,9,11
Durlobactam: Broad‑spectrum β‑lactamase inhibitor8
- Non-β‑lactam diazabicyclooctane β‑lactamase inhibitor8,10
- Mechanism of action: Protects sulbactam from hydrolysis → restores activity of sulbactam8-10
Slide table to view more
Spectrum of in vitro β‑lactamase
inhibitor activity9,12,13,a
inhibitorb
broad activity
Clinical significance cannot be inferred from in vitro data.
Approved indications may not include carbapenem-resistant Acinetobacter baumannii.
+, active against β‑lactamases; -, not active against β‑lactamases, ±, active against select β‑lactamases.
In vitro activity against Acinetobacter
5,032 Acinetobacter baumannii-calcoaceticus complex global clinical isolates from 2016-202110
Slide table to view more
| Antimicrobial Agent | MIC90 (μg/mL) | MIC Range (μg/mL) | % Susceptible |
|---|---|---|---|
| XACDURO† | 2 | ≤0.03 to >64 | 98.3 |
| Sulbactam† | 64 | 0.25 to >64 | 46.9 |
| Cefepime | >16 | ≤0.12 to >16 | 44.6 |
| Imipenem | >64 | ≤0.03 to >64 | 48.9 |
| Meropenem | >64 | ≤0.03 to >64 | 47.9 |
| Amikacin | >64 | ≤0.5 to >64 | 58.6 |
| Ciprofloxacin | >4 | ≤0.12 to >4 | 44.4 |
| Colistin | 1 | ≤0.25 to >8 | NA |
| Minocycline | 16 | ≤0.12 to >16 | 78.3 |
MIC interpretation as published by CLSI (CLSI M100 2021). For XACDURO, a susceptibility breakpoint of 4/4 μg/mL was used. Sulbactam MICs were interpreted using the sulbactam component of CLSI M100 (2021) ampicillin-sulbactam MIC breakpoints (≤8/4 [susceptible], 16/8 [intermediate], and ≥32/16 [resistant]) given that sulbactam is well established to comprise the active component of the combination for Acinetobacter spp.10,14
Identifying potential patients
Can XACDURO make a difference for your patients?
Not an actual patient.
Joyce, 79
Resides in skilled nursing facility
Condition:
Critically ill and hospitalized
Current Diagnosis:
HABP caused by Acinetobacter baumannii
Medical History:
Hypertension, ischemic heart disease, and atrial fibrillation
Antibiotic History:
NA
Not an actual patient.
Evan, 62
Resides in long-term care (LTC) facility
Condition:
Critically ill and hospitalized
Current Diagnosis:
Multidrug resistant A. baumannii necrotizing pneumonia (VABP) complicated with empyema
Medical History:
COPD, hypertension, renal insufficiency
Antibiotic History:
~90 days ago for community‑acquired bacterial pneumonia within LTC facility
A. baumannii, Acinetobacter baumannii; COPD=chronic obstructive pulmonary disease.
Want to know more?
Request to speak with a XACDURO sales representative or receive information.
Treat with Precision.
Choose pathogen-targeted coverage for HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex with XACDURO.15
References:
1. Centers for Disease Control and Prevention (CDC). Antimicrobial resistance threats in the United States, 2021-2022. Available at: https://www.cdc.gov/antimicrobial-resistance/media/pdfs/antimicrobial-resistance-threats-update-2022-508.pdf. Accessed April 4, 2025 2. Antimicrobial Resistance Collaborators. Lancet. 2022;399(10325):629‑655. doi:10.1016/S0140‑6736(21)02724‑0 3. Appaneal HJ, et al. Antimicrob Agents Chemother. 2022;66(3):e0197521. doi:10.1128/AAC.01975‑21 4. World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. Accessed June 28, 2023. https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Published February 27, 2017 5. Centers for Disease Control and Prevention (CDC). Carbapenem‑resistant Acinetobacter baumannii (CRAB): An urgent public health threat in United States healthcare facilities. Available at: https://arpsp.cdc.gov/story/cra-urgent-public-health-threat. Last accessed April 1, 2025. 6. Ling W, et al. JAC Antimicrob Resist. 2021;3(4):dlab157. doi:10.1093/jacamr/dlab157 7. Pogue JM, et al. BMC Infect Dis. 2022;22(1):36. doi:10.1186/s12879‑021‑07024‑4 8. XACDURO®. Package Insert. Innoviva Specialty Therapeutics, Inc.; 2023. 9. Papp-Wallace KM, McLeod SM, Miller AA. Clin Infect Dis. 2023;76(Suppl 2):S194‑S201. doi:10.1093/cid/ciad095 10. Karlowsky JA, et al. Antimicrob Agents Chemother. 2022;66(9):e007812. doi:10.1128/aac.00781‑22 11. Penwell WF et al. Antimicrob Agents Chemother. 2015;59(3):1680‑1689. doi:10.1128/AAC.04808‑14 12. Eiamphungporn W, et al. Int J Mol Sci. 2018;19(8):2222. doi:10.3390/ijms19082222 13. Vázquez‑Ucha JC, et al. Int J Mol Sci. 2020;21(23):9308. doi:10.3390/ijms21239308 14. Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing. M100, 31st ed. CLSI, Wayne, PA. 15. Kaye KS, et al. Lancet Infect Dis. 2023;11:s1473‑3099(23)00184‑6. doi:10.1016/s1473‑3099(23)00184‑6